Entrada Therapeutics (TRDA) Net Cash Flow (2020 - 2026)

Entrada Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$14.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 56.23% year-over-year to -$14.6 million; the TTM figure through Mar 2026 stood at $7.9 million (up 1427.05% YoY), while the FY2025 annual figure was -$10.8 million, down 132.18% from the prior year.
• Net Cash Flow was -$14.6 million for Q1 2026 at Entrada Therapeutics, down from -$2.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $182.5 million in Q1 2023 to a low of -$202.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$12.4 million across 5 years, with a median of -$2.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow soared 292.79% in 2023, then slumped 4101.68% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$8.2 million in 2022, then jumped by 292.79% to $15.7 million in 2023, then soared by 47.34% to $23.2 million in 2024, then tumbled by 112.49% to -$2.9 million in 2025, then tumbled by 405.12% to -$14.6 million in 2026.
• The last three Net Cash Flow figures came in at -$14.6 million (Q1 2026), -$2.9 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.